For patients with type 1 diabetes, achieving the glycemic target recommended by the American Diabetes Association remains challenging, despite the use of insulin pumps, sensors for continuous glucose monitoring, the combination of these technologies (sensor-augmented pump), and systems that automatically suspend insulin delivery when glucose values fall below or are about to reach a prespecified threshold (low-glucose and predicted-low-glucose suspend features, respectively).¹ The artificial pancreas, also called the closed-loop system, is a further step toward automated insulin delivery, addressing both hypoglycemia and hyperglycemia. It consists of an insulin pump, a glucose sensor, and an algorithm that continuously modifies the rate . . .